In vitro and physiologically‐based pharmacokinetic based assessment of drug–drug interaction potential of canagliflozin

AIMS: Canagliflozin is a recently approved drug for use in the treatment of type 2 diabetes. The potential for canagliflozin to cause clinical drug–drug interactions (DDIs) was assessed. METHODS: DDI potential of canagliflozin was investigated using in vitro test systems containing drug metabolizing...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Clin Pharmacol
Main Authors: Mamidi, Rao N. V. S., Dallas, Shannon, Sensenhauser, Carlo, Lim, Heng Keang, Scheers, Ellen, Verboven, Peter, Cuyckens, Filip, Leclercq, Laurent, Evans, David C., Kelley, Michael F., Johnson, Mark D., Snoeys, Jan
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2016
Assuntos:
Drug Interactions
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5401984/
https://ncbi.nlm.nih.gov/pubmed/27862160
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13186
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados